<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059344</url>
  </required_header>
  <id_info>
    <org_study_id>TP0203</org_study_id>
    <nct_id>NCT01059344</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis</brief_title>
  <official_title>A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tillotts Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tillotts Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to determine the efficacy of Asacol™ 4.8 g/day (800 mg
      tablets) to induce clinical and endoscopic remission after 6 weeks of treatment compared to
      placebo in subjects with active ulcerative colitis (UC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 800 mg Asacol™ tablets from Tillotts Pharma AG are being marketed in over 30 countries,
      mainly in Europe and Asia. Approved dosages for the treatment of active UC are between 2.4
      and 4.8 g/day in analogy to the approved 400 mg dosage form. The present trial is planned to
      generate efficacy data to support the safe use of a 4.8 g/day dose of the 800 mg dosage form
      in a well defined population of patients with mildly to moderately active UC. In keeping with
      the EMEA UC guideline the study will have a placebo-controlled 6 weeks induction treatment.
      After 6 weeks, treatment success will be evaluated using the modified UC disease activity
      index as primary efficacy measurement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC).</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical remission defined as stool frequency score of 0, rectal bleeding score of 0, no urgency</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>10 weeks</time_frame>
    <description>Clinical remission defined as a score of 0 for stool frequency, 0 for rectal bleeding and no urgency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Remission</measure>
    <time_frame>6 weeks</time_frame>
    <description>Endoscopic remission is defined as a sigmoidoscopy score of 1 or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Remission</measure>
    <time_frame>10 weeks</time_frame>
    <description>Endoscopic remission is defined as a sigmoidoscopy score of 1 or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement</measure>
    <time_frame>6 weeks</time_frame>
    <description>Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement</measure>
    <time_frame>10 weeks</time_frame>
    <description>Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mesalamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4.8g Mesalamin (800mg tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4.8g Placebo to Mesalamin (800 mg tablet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesalamin</intervention_name>
    <description>4.8g/day, 800 mg tablets</description>
    <arm_group_label>Mesalamin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Asacol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (1) Male or non-pregnant, non-lactating females, 18 years of age or older. (2) Documented
        diagnosis of UC with disease extending at least 15 cm from the anal verge.

        (3) Active UC defined by:

        (a) modified UC-DAI score of 4-10 with (b) sigmoidoscopy component score ≥ 2 and (c) rectal
        bleeding component score ≥ 1 (4) Ability of subject to participate fully in all aspects of
        this clinical trial.

        (5) Written informed consent must be obtained and documented.

        Exclusion Criteria:

          1. Severe UC defined by the following criteria:

             ³6 bloody stools daily with one or more of the following:

               1. oral temperature &gt; 37.8°C or &gt; 100.0°F

               2. pulse &gt; 90/min

               3. hemoglobin &lt; 10 g/dL

          2. Previously failed treatment with a mesalazine dose of &gt; 2.0 g/day.

          3. Current relapse lasting &gt; 6 weeks in the opinion of the investigator.

          4. Treatment with 5-ASA at a dose of &gt;2.0g/day within 1 week prior to randomisation

          5. Treatment with systemic or rectal steroids within 4 weeks prior to randomization.

          6. Treatment with immunosuppressants within 6 weeks prior to randomization.

          7. Treatment with infliximab or other biologics within 3 months prior to randomization.

          8. Treatment with systemic antibiotics for UC within 7 days prior to randomization.

          9. Treatment with probiotics within 7 days prior to randomization.

         10. Treatment with anti-diarrheals within 7 days prior to randomization.

         11. Treatment with nicotine patch within 7 days prior to randomization.

         12. Received any investigational drug within 30 days prior to randomization.

         13. History of colectomy or partial colectomy.

         14. History of definite dysplasia in colonic biopsies.

         15. Crohn's disease.

         16. Known bleeding disorders.

         17. Immediate or significant risk of toxic megacolon.

         18. Hypersensitivity to salicylates, aspirin, sulfasalazine or 5-ASA.

         19. Serum creatinine &gt; 1.5 times the upper limit of the normal range.

         20. AST, ALT, total bilirubin or alkaline phosphatase &gt; 2 times the upper limit of the
             normal range.

         21. Serious underlying disease other than UC which in the opinion of the investigator may
             interfere with the subject's ability to participate fully in the study.

         22. History of alcohol or drug abuse which in the opinion of the investigator may
             interfere with the subject's ability to comply with the study procedures.

         23. Stools positive for clostridium difficile.

         24. Pregnant or lactating women.

         25. Prior enrolment in the current study and had received study treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Feagan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Robarts Clinical Trials Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital, 9</name>
      <address>
        <city>Gomel</city>
        <zip>23602</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No.1</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minsk Regional Clinical Hospital, 41</name>
      <address>
        <city>Minsk</city>
        <zip>2230</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital No. 2</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.Klumov City Clinical Hospital No. 3</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <zip>210037</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medwin Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhrapradesh</state>
        <zip>500 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osmania General Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhrapradesh</state>
        <zip>500 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.S.Ramiah Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Gokulam Medical College and Research Foundation</name>
      <address>
        <city>Trivandrum</city>
        <state>Kerala</state>
        <zip>695 607</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. R. Kalla Memorial Gastro and General Hospital</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Life Line Hospital</name>
      <address>
        <city>Chennai</city>
        <state>TamilNadu</state>
        <zip>600 096</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maulana Azad Medical College and Associated Lok Nayak Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of liver and billiary sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110 070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Sihhiye</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty Sihhiye</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty Besevler</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dicle University Medical Faculty</name>
      <address>
        <city>Diyarbakir</city>
        <zip>21280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trakya University Medical Faculty</name>
      <address>
        <city>Edirne</city>
        <zip>22030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gaziantep University Medical Faculty Kampus Alani</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisli Etfal Egitim ve Arastirma Hospital Sisli</name>
      <address>
        <city>Istanbul</city>
        <zip>34360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul University Medical Faculty Inciralti</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ataturk Egitim ve Arastirma Hospital Basin Sitesi</name>
      <address>
        <city>Izmir</city>
        <zip>35360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovska derzhavna medychna akademiia,</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>4904</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivskyi natsionalnyi medychnyi universytet,</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miska klinichna likarnia 2,</name>
      <address>
        <city>Kharkiv</city>
        <zip>61001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalnyi medychnyi universytet im. Bogomoltsia, kafedra khirurgii 1 na bazi viddilennia proctologii Miskoi klinichnoi likarni 18, m.Kyiv</name>
      <address>
        <city>Kyiv</city>
        <zip>01030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalnyi medychnyi universytet im. O.O. Bogomoltsia,</name>
      <address>
        <city>Kyiv</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natsionalna medychna akademia pisliadyplomnoi osvity im. P.L. Shupyk,</name>
      <address>
        <city>Kyiv</city>
        <zip>04201</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lvivskyi natsionalnyi medychnyi universytet imeni Danyla Galytskogo,</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odeska oblasna klinichna likarnia, Oblasnyi tsentr gastroenterologii,</name>
      <address>
        <city>Odessa</city>
        <zip>65039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>India</country>
    <country>Turkey</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>March 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2017</results_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mesalamine</keyword>
  <keyword>Asacol</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>induction therapy</keyword>
  <keyword>acute disease</keyword>
  <keyword>mild to moderate</keyword>
  <keyword>Active Ulcerative Colitis (mild to moderate)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>November 2009 - February 2011</recruitment_details>
      <pre_assignment_details>Screen failures, not complying to inclusion and exclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mesalamin</title>
          <description>Mesalamin: 4.8g/day, 800 mg tablets</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mesalamin</title>
          <description>Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the Asacol™ 4.8 g/day treatment group will receive three 800 mg Asacol™ tablets in the morning and three 800 mg Asacol™ tablets in the evening.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the placebo treatment group will receive three placebo tablets in the morning and three placebo tablets in the evening.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="141"/>
            <count group_id="B3" value="281"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="14.3"/>
                    <measurement group_id="B2" value="40.72" spread="13.8"/>
                    <measurement group_id="B3" value="41.8" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belarus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC).</title>
        <description>Clinical remission defined as stool frequency score of 0, rectal bleeding score of 0, no urgency</description>
        <time_frame>6 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamin</title>
            <description>Mesalamin: 4.8g/day, 800 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC).</title>
          <description>Clinical remission defined as stool frequency score of 0, rectal bleeding score of 0, no urgency</description>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.069</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Remission</title>
        <description>Clinical remission defined as a score of 0 for stool frequency, 0 for rectal bleeding and no urgency</description>
        <time_frame>10 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamin</title>
            <description>Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the Asacol™ 4.8 g/day treatment group will receive three 800 mg Asacol™ tablets in the morning and three 800 mg Asacol™ tablets in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the placebo treatment group will receive three placebo tablets in the morning and three placebo tablets in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Remission</title>
          <description>Clinical remission defined as a score of 0 for stool frequency, 0 for rectal bleeding and no urgency</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Remission</title>
        <description>Endoscopic remission is defined as a sigmoidoscopy score of 1 or less</description>
        <time_frame>6 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamin</title>
            <description>Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the Asacol™ 4.8 g/day treatment group will receive three 800 mg Asacol™ tablets in the morning and three 800 mg Asacol™ tablets in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the placebo treatment group will receive three placebo tablets in the morning and three placebo tablets in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Remission</title>
          <description>Endoscopic remission is defined as a sigmoidoscopy score of 1 or less</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endoscopic Remission</title>
        <description>Endoscopic remission is defined as a sigmoidoscopy score of 1 or less</description>
        <time_frame>10 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamin</title>
            <description>Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the Asacol™ 4.8 g/day treatment group will receive three 800 mg Asacol™ tablets in the morning and three 800 mg Asacol™ tablets in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the placebo treatment group will receive three placebo tablets in the morning and three placebo tablets in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Endoscopic Remission</title>
          <description>Endoscopic remission is defined as a sigmoidoscopy score of 1 or less</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement</title>
        <description>Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)</description>
        <time_frame>6 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamin</title>
            <description>Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the Asacol™ 4.8 g/day treatment group will receive three 800 mg Asacol™ tablets in the morning and three 800 mg Asacol™ tablets in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the placebo treatment group will receive three placebo tablets in the morning and three placebo tablets in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement</title>
          <description>Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement</title>
        <description>Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)</description>
        <time_frame>10 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamin</title>
            <description>Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the Asacol™ 4.8 g/day treatment group will receive three 800 mg Asacol™ tablets in the morning and three 800 mg Asacol™ tablets in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets The study drug will be given for 10 weeks. All treatment regimens will be orally administered, with or without food. Subjects randomized to the placebo treatment group will receive three placebo tablets in the morning and three placebo tablets in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement</title>
          <description>Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>To Achieve Clinical Remission in the Patient Population Confirmed by the Central Reader</title>
        <description>Clinical Remission, defined as stool frequency score of 0, rectal bleeding score of 0 and absence of urgency in subjects with adequate disease extent at baseline confirmed by central reading.</description>
        <time_frame>6 weeks</time_frame>
        <population>modified ITT, eligibility confirmed by central reader</population>
        <group_list>
          <group group_id="O1">
            <title>Mesalamin</title>
            <description>Mesalamin: 4.8g/day, 800 mg tablets</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets</description>
          </group>
        </group_list>
        <measure>
          <title>To Achieve Clinical Remission in the Patient Population Confirmed by the Central Reader</title>
          <description>Clinical Remission, defined as stool frequency score of 0, rectal bleeding score of 0 and absence of urgency in subjects with adequate disease extent at baseline confirmed by central reading.</description>
          <population>modified ITT, eligibility confirmed by central reader</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>19 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mesalamin</title>
          <description>Mesalamin: 4.8g/day, 800 mg tablets</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to Mesalamin: 4.8g/day, 800 mg tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerosa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="140"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerosa</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="140"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Monozytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Investigator endoscopy scores resultet in 31% patients with insuficient disease severity at baseline. Central reader scores were used for a post hoc analysis of the primary endpoint, including patients with pre-specified disease severity only.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Brian G. Feagan et al</name_or_title>
      <organization>The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcertive Colitis</organization>
      <phone>Gastroenterology 2013; 145: ext 149-157</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

